公开(公告)号：WO2020117962A1

公开(公告)日：2020-06-11

申请号：PCT/US2019/064516

申请日：2019-12-04

申请人： VIKING THERAPEUTICS, INC.

发明人： LIAN, Brian ,  MASAMUNE, Hiroko ,  BARKER, Geoffrey

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61K31/192 ,  A61K31/196 ,  A61K31/198 ,  A61K31/404 ,  A61K31/40 ,  A61K31/53 ,  A61P1/16 ,  A61P11/00 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β–dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：WO2020117987A1

公开(公告)日：2020-06-11

申请号：PCT/US2019/064548

申请日：2019-12-04

申请人： VIKING THERAPEUTICS, INC.

发明人： LIAN, Brian ,  MASAMUNE, Hiroko

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61K31/53 ,  A61K31/40 ,  A61K31/428 ,  A61K31/192 ,  A61K31/216 ,  A61K31/575 ,  A61K31/4178 ,  A61K31/46 ,  A61K38/26 ,  A61P1/16 ,  A61P19/04

摘要： The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

公开(公告)号：WO2018053036A1

公开(公告)日：2018-03-22

申请号：PCT/US2017/051410

申请日：2017-09-13

申请人： VIKING THERAPEUTICS, INC. ,  METABASIS THERAPEUTICS, INC.

发明人： LIAN, Brian ,  MASAMUNE, Hiroko ,  ERION, Mark ,  ITO, Bruce

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61P5/14 ,  A61P3/06 ,  A61P3/04 ,  A61P1/16

摘要： The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders is maintained, while thyroid- related and thyroid axis-related side effects are reduced or eliminated.

摘要翻译： 本公开涉及甲状腺激素受体激动剂的施用方法。 本公开内容提供了方法，其中给定的甲状腺受体激动剂在改善或治疗肥胖症，高脂血症，高胆固醇血症，糖尿病，非酒精性脂肪肝病，非酒精性脂肪性肝炎，动脉粥样硬化，心血管疾病，甲状腺机能减退症和相关病症中的活性得以维持， 而甲状腺相关的和甲状腺轴相关的副作用减少或消除。

公开(公告)号：WO2019183004A1

公开(公告)日：2019-09-26

申请号：PCT/US2019/022824

申请日：2019-03-18

申请人： VIKING THERAPEUTICS, INC.

发明人： LIAN, Brian ,  MASAMUNE, Hiroko ,  BARKER, Geoffrey

IPC分类号： C07F9/6571 ,  A61K31/683

摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

公开(公告)号：WO2018226604A1

公开(公告)日：2018-12-13

申请号：PCT/US2018/035909

申请日：2018-06-04

申请人： VIKING THERAPEUTICS, INC.

发明人： LIAN, Brian ,  MASAMUNE, Hiroko ,  BARKER, Geoffrey, T.

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61P1/16 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β –dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.